Bruker (NASDAQ:BRKR)‘s stock had its “equal weight” rating reiterated by equities research analysts at Morgan Stanley in a report issued on Thursday. They currently have a $35.00 price target on the medical research company’s stock. Morgan Stanley’s price objective indicates a potential upside of 2.37% from the company’s current price.

Several other equities research analysts have also commented on BRKR. BidaskClub upgraded shares of Bruker from a “hold” rating to a “buy” rating in a research note on Wednesday, August 16th. Goldman Sachs Group restated a “sell” rating and issued a $24.00 price target on shares of Bruker in a research note on Tuesday, September 26th. J P Morgan Chase & Co upgraded shares of Bruker from an “underweight” rating to a “neutral” rating and set a $28.00 price target on the stock in a research note on Friday, November 3rd. Cowen restated a “hold” rating and issued a $29.00 price target on shares of Bruker in a research note on Friday, November 3rd. Finally, Bank of America upgraded shares of Bruker from an “underperform” rating to a “neutral” rating and set a $34.00 price target on the stock in a research note on Friday, November 3rd. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and four have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $30.08.

Bruker (BRKR) traded down $0.09 on Thursday, reaching $34.19. 623,800 shares of the company traded hands, compared to its average volume of 627,637. Bruker has a 52-week low of $21.03 and a 52-week high of $36.53. The firm has a market capitalization of $5,332.69, a price-to-earnings ratio of 29.30, a price-to-earnings-growth ratio of 2.90 and a beta of 1.12. The company has a current ratio of 2.60, a quick ratio of 1.60 and a debt-to-equity ratio of 0.65.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Thursday, November 2nd. The medical research company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.27 by $0.02. Bruker had a net margin of 8.85% and a return on equity of 25.83%. The company had revenue of $435.60 million for the quarter, compared to analyst estimates of $415.45 million. During the same quarter last year, the business earned $0.32 earnings per share. Bruker’s revenue was up 10.6% compared to the same quarter last year. equities analysts anticipate that Bruker will post 1.19 EPS for the current year.

Institutional investors have recently bought and sold shares of the company. Acrospire Investment Management LLC boosted its holdings in shares of Bruker by 496.1% in the second quarter. Acrospire Investment Management LLC now owns 3,827 shares of the medical research company’s stock valued at $110,000 after acquiring an additional 3,185 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Bruker in the second quarter valued at approximately $111,000. Zions Bancorporation bought a new position in shares of Bruker in the third quarter valued at approximately $119,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Bruker by 11.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,599 shares of the medical research company’s stock valued at $133,000 after acquiring an additional 467 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of Bruker by 7.1% in the second quarter. The Manufacturers Life Insurance Company now owns 5,003 shares of the medical research company’s stock valued at $144,000 after acquiring an additional 331 shares in the last quarter. Institutional investors and hedge funds own 65.63% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Bruker’s (BRKR) “Equal Weight” Rating Reiterated at Morgan Stanley” was originally published by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/12/14/brukers-brkr-equal-weight-rating-reiterated-at-morgan-stanley.html.

Bruker Company Profile

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Analyst Recommendations for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.